More specifically, the administration of CAFs that overexpress NEAT1 leads to enhanced EC tumor volume and increased proliferation capacity, as demonstrated by the elevated percentage of proliferation index marker Ki-67-immunopositive tumor cells. Here, NEAT1 is linked to neoplasm.